Blinatumomab
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALL, Childhood
Conditions
ALL, Childhood, Minimal Residual Disease
Trial Timeline
Dec 17, 2020 → Jan 22, 2022
NCT ID
NCT04785547About Blinatumomab
Blinatumomab is a phase 2 stage product being developed by Amgen for ALL, Childhood. The current trial status is terminated. This product is registered under clinical trial identifier NCT04785547. Target conditions include ALL, Childhood, Minimal Residual Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02187354 | Pre-clinical | Completed |
| NCT07192237 | Phase 2 | Recruiting |
| NCT07134088 | Phase 1/2 | Recruiting |
| NCT06649006 | Phase 1 | Completed |
| NCT06054113 | Phase 2 | Active |
| NCT04448834 | Phase 2 | Withdrawn |
| NCT04506086 | Approved | Terminated |
| NCT04746209 | Phase 2 | Recruiting |
| NCT04521231 | Phase 1/2 | Recruiting |
| NCT04556084 | Phase 2 | Terminated |
| NCT04785547 | Phase 2 | Terminated |
| NCT04044560 | Phase 2 | Terminated |
| NCT03751709 | Phase 1 | Completed |
| NCT03298412 | Phase 2 | Terminated |
| NCT02961881 | Phase 1 | Completed |
| NCT02910063 | Phase 2/3 | Completed |
| NCT02807883 | Phase 2 | Completed |
| NCT02811679 | Phase 2 | Terminated |
| NCT02412306 | Phase 1/2 | Completed |
| NCT02000427 | Phase 2 | Completed |
Competing Products
20 competing products in ALL, Childhood